Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MCRBNASDAQ:MDCXNASDAQ:SKYENASDAQ:SNYR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMCRBSeres Therapeutics$7.41+9.5%$11.06$6.53▼$30.60$64.70M2.89147,633 shs141,084 shsMDCXMedicus Pharma$5.95-5.9%$3.86$1.80▼$6.98$79.90MN/A63,263 shs247,240 shsSKYESkye Bioscience$2.01+5.8%$1.79$1.14▼$13.44$62.26M1.74360,039 shs139,700 shsSNYRSynergy CHC Corp. (Uplisting)$2.14+10.3%$2.40$0.12▼$10.00$18.73MN/A745,736 shs114,048 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMCRBSeres Therapeutics-8.14%-18.34%-48.97%-59.70%-62.22%MDCXMedicus Pharma+14.91%+48.01%+75.07%+105.19%+631,999,900.00%SKYESkye Bioscience+0.05%+6.65%+35.73%-36.57%-84.02%SNYRSynergy CHC Corp. (Uplisting)+2.86%+7.18%+8.38%-44.57%+193,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMCRBSeres Therapeutics3.5162 of 5 stars2.93.00.04.61.91.70.0MDCXMedicus PharmaN/AN/AN/AN/AN/AN/AN/AN/ASKYESkye Bioscience1.4392 of 5 stars3.51.00.00.03.40.00.0SNYRSynergy CHC Corp. (Uplisting)3.6277 of 5 stars3.80.00.00.04.11.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMCRBSeres Therapeutics 1.80Reduce$73.67894.15% UpsideMDCXMedicus Pharma 3.50Strong Buy$23.50294.96% UpsideSKYESkye Bioscience 3.00Buy$16.60725.87% UpsideSNYRSynergy CHC Corp. (Uplisting) 3.50Strong Buy$10.00367.29% UpsideCurrent Analyst Ratings BreakdownLatest SNYR, SKYE, MDCX, and MCRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $27.005/8/2025MCRBSeres TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$1.25 ➝ $6.005/8/2025MDCXMedicus PharmaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $20.004/28/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/21/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/14/2025MDCXMedicus PharmaD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/14/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.003/21/2025SKYESkye BioscienceCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $14.003/21/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/20/2025MCRBSeres TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/14/2025MCRBSeres TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$20.00 ➝ $15.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMCRBSeres Therapeutics$126.33M0.51N/AN/A($0.35) per share-21.17MDCXMedicus PharmaN/AN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/A($0.17) per shareN/ASNYRSynergy CHC Corp. (Uplisting)$34.83M0.54N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMCRBSeres Therapeutics-$113.72M-$4.60N/AN/AN/AN/AN/A-55.08%N/AMDCXMedicus PharmaN/AN/A0.00N/AN/AN/AN/AN/A6/27/2025 (Estimated)SKYESkye Bioscience-$37.65M-$0.82N/AN/AN/AN/A-45.78%-37.44%N/ASNYRSynergy CHC Corp. (Uplisting)N/AN/A0.003.63N/AN/AN/AN/AN/ALatest SNYR, SKYE, MDCX, and MCRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SNYRSynergy CHC Corp. (Uplisting)$0.07$0.10+$0.03$0.10N/AN/A5/12/2025Q1 2025MDCXMedicus Pharma-$0.23-$0.42-$0.19-$0.42N/AN/A5/8/2025Q1 2025SKYESkye Bioscience-$0.31-$0.28+$0.03-$0.28N/AN/A5/7/2025Q1 2025MCRBSeres Therapeutics-$0.67-$2.24-$1.57$3.75$10.00 millionN/A3/31/2025Q4 2024SNYRSynergy CHC Corp. (Uplisting)$0.10$0.01-$0.09$0.01$10.55 million$10.30 million3/28/2025Q4 2024MDCXMedicus Pharma-$0.32-$0.18+$0.14-$0.18N/AN/A3/20/2025Q4 2024SKYESkye Bioscience-$0.30-$0.24+$0.06-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMCRBSeres TherapeuticsN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/ASNYRSynergy CHC Corp. (Uplisting)N/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMCRBSeres TherapeuticsN/A1.121.12MDCXMedicus PharmaN/AN/AN/ASKYESkye BioscienceN/A14.1914.19SNYRSynergy CHC Corp. (Uplisting)N/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMCRBSeres Therapeutics59.34%MDCXMedicus PharmaN/ASKYESkye Bioscience21.09%SNYRSynergy CHC Corp. (Uplisting)N/AInsider OwnershipCompanyInsider OwnershipMCRBSeres Therapeutics4.70%MDCXMedicus PharmaN/ASKYESkye Bioscience4.50%SNYRSynergy CHC Corp. (Uplisting)N/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMCRBSeres Therapeutics3308.73 million162.03 millionOptionableMDCXMedicus PharmaN/A13.43 millionN/AN/ASKYESkye Bioscience1130.98 million29.43 millionOptionableSNYRSynergy CHC Corp. (Uplisting)408.75 millionN/AN/ASNYR, SKYE, MDCX, and MCRB HeadlinesRecent News About These CompaniesSynergy CHC Corp. Announces First Quarter 2025 Earnings and Conference Call InformationMay 1, 2025 | globenewswire.comSynergy CHC Stock Short Interest Report | NASDAQ:SNYR | BenzingaApril 17, 2025 | benzinga.comSynergy CHC Reports its Eighth Consecutive Quarter of Profitability and its Fourth Quarter and Full Year 2024 Financial ResultsMarch 31, 2025 | markets.businessinsider.comSynergy CHC Corp. Announces Fourth Quarter and Full Year 2024 Earnings and Conference Call InformationMarch 21, 2025 | markets.businessinsider.comRoth MKM Initiates Coverage of Synergy CHC (SNYR) with Buy RecommendationJanuary 22, 2025 | msn.comSynergy CHC Announces 7th Quarter of ProfitabilityDecember 7, 2024 | markets.businessinsider.comSynergy CHC Corp. (Uplisting) (NASDAQ:SNYR) CEO Purchases $2,700,000.00 in StockOctober 25, 2024 | insidertrades.comSynergy CHC Corp. Announces Closing of Initial Public OfferingOctober 24, 2024 | globenewswire.comSynergy CHC Corp. Prices $10.35 Million Initial Public OfferingOctober 22, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNYR, SKYE, MDCX, and MCRB Company DescriptionsSeres Therapeutics NASDAQ:MCRB$7.41 +0.64 (+9.45%) As of 04:00 PM EasternSeres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Medicus Pharma NASDAQ:MDCX$5.95 -0.37 (-5.85%) As of 04:00 PM EasternMedicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.Skye Bioscience NASDAQ:SKYE$2.01 +0.11 (+5.79%) As of 04:00 PM EasternSkye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.Synergy CHC Corp. (Uplisting) NASDAQ:SNYR$2.14 +0.20 (+10.31%) As of 04:00 PM EasternSynergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas An Acquisition Just Made Dick's the Most Exciting Stock in Retail Walmart Stock Alert: Big Price Move Expected Soon Broadcom Set to Surge as AI Diffusion Rule Ends Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock Wins Is Bally’s Turnaround a Safe Bet Amid Mixed Investor Sentiment? SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start Intel Makes a Cool Move With Shell, But Will Investors Warm Up? AMD’s AI-Powered Stock Price Rally Just Shifted Gears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
